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Abstract 
Background 
Inflammatory process is involved in pathogenesis of diabetic nephropathy, although 
the activation and phenotypic change of macrophages in diabetic kidney has 
remained unclear.  Sialoadhesin is a macrophage adhesion molecule containing 17 
extracellular immunoglobulin-like domeins, and is an I-type lectin which binds to sialic 
acid ligands expressed on hematopoietic cells. The aim of this study is to clarify the 
activation and phenotypic change of macrophages in the progression of diabetic 
nephropathy. 
Methods 
We examined the expression of  surface markers for pan-macrophages, resident 
macrophages, sialoadhesin, MHC class II and α-smooth muscle actin in the glomeruli 
of diabetic rats using immunohistochemistry at 0, 1, 4, 12, and 24 weeks after 
induction of diabetes by streptozotocin. Expression of type IV collagen and the change 
of mesangial matrix area were also measured. The mechanism for up-regulated 
expression of sialoadhesin on macrophages was evaluated in vitro. 
Results 
The number of macrophages was increased in diabetic glomeruli at 1 month after 
induction of diabetes and the increased number was maintained until 6 months. On 
the other hand, sialoadhesin-positive macrophages were increased during the late 
stage of diabetes concomitantly with the increase of α-smooth muscle actin positive 
mesangial cells, mesangial matrix area and type IV collagen. Gene expression of 
sialoadhesin was induced by the stimulation with IL-1β and TNF-α but not with IL-4, 
TGF-β and high glucose in cultured human macrophages. 
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Conclusion 
The present findings suggest that sialoadhesin-positive macrophages may contribute 
to the progression of diabetic nephropathy. 
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Introduction 
Diabetic nephropathy is a leading cause of end-stage renal failure in developed 
countries. Infiltration of mononuclear cells is a characteristic of the glomeruli in the 
patients with diabetes (1).  We previously demonstrated that intercellular adhesion 
molecule-1 (ICAM-1) mediates macrophage infiltration into the glomeruli of 
streptozotocin (STZ) -induced diabetic rats (2). Furthermore, we demonstrated that 
infiltration of macrophages was suppressed in diabetic ICAM-1 knockout mice and 
urinary albumin excretion, glomerular hypertrophy and mesangial matrix expansion 
were significantly suppressed in diabetic ICAM-1 knockout mice than in diabetic wild 
type mice (3). These findings strongly suggest the important role of macrophages in 
the progression of diabetic nephropathy, although the state of activation and the 
phenotype of macrophages infiltrated into diabetic glomeruli have remained unclear. 
Sialoadhesin (Sn) is a sialic acid-dependent lectin-like receptor (4) which 
mediates cell to cell interactions. Expression of Sn is normally restricted to the distinct 
subsets of tissue macrophages including lymphoid tissue macrophage (5). Sn is 
induced rapidly in response to serum factors (6), glucocorticoids, and cytokines (7). 
Recent studies in humans have shown that Sn is expressed abundantly on 
macrophages in the pathological tissues of multiple sclerosis, atherosclerosis, 
rheumatoid arthritis, and breast cancer (8), suggesting that Sn-positive macrophages 
is related to chronic inflammation.  
Ito et al. demonstrated that Sn-positive macrophages were observed in the 
prolonged model of mesangial proliferative glomerulonephritis (9). This study 
suggests that Sn-positive macrophages might be involved in the chronic inflammation 
of the kidney. There have been some reports which describe the critical role of 
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Sn-positive macrophages in the pathogenesis of  experimental glomerulonephritis 
(10-12), however little is known about Sn-positive macrophages in the pathogenesis of 
diabetic nephropathy. To elucidate the relationship between Sn-positive macrophages 
and diabetic nephropathy, we analyzed the phenotypes of macrophages in diabetic 
glomeruli by immunohistochemically examining ED1 (pan-macrophages marker), ED2 
(resident macrophages marker), ED3 (Sn-positive macrophages marker) (13). We 
also analyzed the activated macrophages which express OX-6 (MHC class II positive 
cells marker) on the cell surface. 
Diabetic nephropathy is characterized histologically by glomerular hypertrophy, 
glomerular basement membrane thickening, mesangial matrix expansion, and 
ultimately glomerular sclerosis (14-17). In diabetic glomerulosclerosis, there is an 
accumulation of the matrix proteins, type IV collagen or fibronectin (18-19). Because 
the mesangial cells are responsible for this matrix protein synthesis, overproduction of 
these matrix proteins is considered to be a result of phenotypic change in the 
masangial cells (18). Therefore, we also analyzed α-smooth muscle actin (α-SMA) as 
a marker of the phenotypic change of the masangial cells (20-21). Furthermore, we 
examined the expression of ICAM-1, type IV collagen, and mesangial matrix area. 
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Materials and Methods 
Animals 
Male Sprague Dawley (SD) rats were purchased from Charles River Japan 
(Yokohama, Japan). Male SD rats weighting 120 g (4 weeks of age) were used in this 
study. These rats received a standard chow and water diet. All procedures were 
performed according to the Guidelines for Animal Experiments at Okayama University 
Medical School, Japanese Government Animal Protection and Management Law (No. 
105) and Japanese Government Notification on Feeding and Safekeeping of Animals 
(No. 6). 
 
Induction of diabetes 
Diabetes was induced in 25 rats by the intravenous injection of 65 mg/kg STZ 
(Sigma-Aldrich, St. Louis, MO) in 10 mM citrate buffer solution (pH 4.5). The control 
rats were injected with citrate buffer alone. Blood was collected from a tail vein and 
assayed for glucose. Urinary protein was determined by the biuret method. Five 
diabetic and five control rats were sacrificed under anaesthesia and the kidneys were 
harvested at 1, 4, 12, 24 weeks after the injection with STZ or buffer. Kidneys were 
weighed and fixed in 10% formalin for periodic acid-methenamine-silver (PAM) 
staining and the remaining tissues were embedded in OCT compound (Sakura 
Finetechnical Co., Tokyo, Japan) and immediately frozen in acetone cooled on dry ice. 
Metabolic data were measured as described previously (2). 
 
Metabolic data 
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Blood glucose, urinary albumin excretion (24 hours), and body weight were measured 
at 0, 1, 4, 12, and 24 weeks. Urine collection was performed for 24 hours with each rat 
individually housed in a metabolic cage and having free access to food and water. 
Blood glucose was measured by the glucose oxidase method. Urinary albumin 
concentration was measured by nephelometry (Organon Teknika-Cappel, Durham, 
NC). Glycosylated hemoglobin (HbA1c) was measured at 0, 1, 4, 12, and 24 weeks 
after induction of diabetes by latex-agglutination assay. 
 
Effect of Insulin treatment 
Three days after the administration of STZ, when all animals (n=5) exhibited blood 
glucose levels >300mg/dl, insulin treatment was initiated using nearly 24 hour acting 
Humalin N (Shionogi, Osaka, Japan) as described previously (2). All insulin-treated 
rats were sacrificed at 4 weeks and processed for immunohistochemical study. 
 
Antibodies 
As primary antibodies, we used mouse antibodies against rat pan-macrophages 
(ED1), resident macrophages (ED2), sialoadhesin-positive macrophages (ED3), and 
MHC class II positive cells (OX6), and these antibodies were purchased from AbD 
Serotec (Oxford, UK). Mouse anti-rat ICAM-1 monoclonal antibody was purchased 
from Seikagaku Corporation (Tokyo, Japan). Rabbit anti-mouse collagen IV antibody 
was purchased from LSL (Tokyo, Japan). Mouse anti α-SMA monoclonal antibody 
was purchased from Oncogene (Boston, MA).  
As secondary antibodies, biotinylated goat anti mouse IgG and fluorescein 
isothiocyanate (FITC)-labeled goat anti mouse IgG were obtained from Jackson 
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Immunoresearch Laboratories (West Grove, PA). Rodamin-labeled anti mouse IgG 
was obtained from Chemicon International (Temecula, CA). FITC-labeled anti rabbit 
IgG was obtained from Zymed Laboratories (San Francisco, CA). 
 
Histopathological examination 
Immunoperoxidase and immunofluorescence staining were performed as described 
previously (2). Fresh frozen sections were cut at 4-μm thickness using a cryostat. To 
evaluate the phenotype of infiltrated macrophages, anti-ED1, ED2, and ED3 
antibodies were applied to the fresh frozen sections as the primary reaction, followed 
by a second reaction with rodamin-labeled anti-mouse IgG antibody. Then 
FITC-labeled anti-rat OX-6 antibody was double stained. Intraglomerular ED1, ED2, 
ED3, and OX-6 positive cells were counted in 10 glomeruli per animal (total 50 
glomeruli for each group). The average number per glomerulus was used for the 
estimation. ICAM-1 and type IV collagen were also detected by the indirect 
immunofluorescence method. Briefly, sections were fixed with cold acetone for 3 min 
and stained with each monoclonal antibodies for 24 h at 4°C. Then, the sections were 
stained with each FITC-labeled anti IgG antibody for 30 min at room temperature.  The 
sections were washed in PBS, mounted with PermaFluor (Shandon, Pittsburgh, PA) 
and examined under a fluorescence microscope (LSM-510, Carl Zeiss, Jena, 
Germany). The intensity of ICAM-1 and type IV collagen in the glomeruli was 
evaluated semi-quantitatively from 0 to 3+. 
The distribution of α-SMA was evaluated by immunoperoxidase assays using 
Vectastain (Vector, Burlingame, CA). In brief, the frozen sections (4-μm thick) were 
fixed with cold acetone for 3 min and nonspecific protein binding was blocked by 
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incubation with normal goat serum and avidin for 20 min.  The sections were first 
incubated with each monoclonal antibodies for 24 hours at 4°C.  Then the sections 
were incubated with biotin-labeled anti IgG antibody for 30 min at room temperature.  
Endogenous peroxidase activity was blocked by incubating the sections in methanol 
containing 0.3% H2O2 for 30 min.  After that, the sections were stained with a 
Vectastain ABC kit.  The sections were then counterstained with Mayer’s hematoxylin 
and the percentage of α-SMA-positive glomeruli was evaluated. 
 
Light microscopy 
Renal tissues were fixed in 10% formalin and embedded in paraffin in a routine fashion. 
Tissue sections were cut at 4-μm thickness, dewaxed and stained with PAM. To 
evaluate glomerular size, randomly selected 5 glomeruli in the cortex per animal were 
examined under high magnification (x200). Mesangial matrix area was defined as the 
PAM-positive area within the tuft area and was measured using Photoshop software 
Ver. 6 (Adobe Systems, San Jose, CA) and analyzed by Scion Image Ver.4.0.2. The 
results are expressed as mean ± SEM (μm2). 
 
Cell culture  
The human monocytic cell line THP-1 (Japanese Collection of Research Bioresources, 
Tokyo, Japan) was cultured in RPMI-1640 (GIBCO/Invitrogen, Carlsbad, CA) 
supplemented with heat-inactivated 10% (vol/vol) fetal bovine serum (Thermo Fisher 
Scientific, Waltham, MA). Cells were cultured at 37°C in humidified air containing 5% 
CO2. For experiments, the cells were adjusted to the cell density of 106 cells/ml in the 
same culture medium. Cells were stimulated with recombinant human tumor necrosis 
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factor-α (TNF-α: 0.01 μg/l to 10 μg/l) (R&D systems, Mineapolis, MN), recombinant 
human interleukin-1β (IL-1β: 0.01 μg/l to 10 μg/l) (R&D systems), recombinant human 
IL-4 (10 μg/l) (R&D systems) and recombinant human transforming growth factor-β1 
(TGF-β1: 10 μg/l) (R&D systems). Cells were also stimulated on hyperglycemic 
condition (5.4 g/l D-glucose) (Sigma-Aldrich); as an osmotic control, D-Mannitol (3.63 
g/l) (Sigma-Aldrich) was added to culture medium in simultaneous wells. Total RNA 
was extracted from THP-1 cells 24 hours after stimulation. 
 
RNA extraction and Quantitative real-time RT-PCR  
Total RNA was extracted using the RNeasy plus mini kit (Qiagen, Valencia, CA, USA) 
according to the manufacturer’s instructions. Single-strand complementary DNA was 
synthesized from the extracted RNA using a GeneAmp RNA PCR Core kit (Applied 
Biosystems, Foster City, CA) according to the manufacturer’s instructions. To evaluate 
mRNA expression of Sn in THP-1 cells, and IL-1β and TNF-α in rat kidney, quantitative 
real-time RT-PCR was performed using a Light Cycler (Roche Diagnostics, Tokyo, 
Japan) and SYBR Premix Ex Taq II (Takara Bio, Shiga, Japan) as previously 
described (22). The mRNA expression was normalized with a house-keeping gene 
(GAPDH or β-actin) in each sample by calculating the relative expression ratio. For 
amplification of the complementary DNA, the following oligonucleotide primers were 
purchased from Takara Bio: Sn, sense 5′-CTGCGAATCAGGGACCAACA-3′, 
antisense 5′-TTTCAACCCAAATCCTAGAGCAGAG-3′; IL-1β, sense 
5′-GCTGTGGCAGCTACCTATGTCTTG-3′, antisense 
5′-AGGTCGTCATCATCCCACGAG-3′; TNF-α, sense 
5′-TCAGTTCCATGGCCCAGAC-3′, antisense 
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5′-GTTGTCTTTGAGATCCATGCCATT-3′; GAPDH, sense 
5′-GCACCGTCAAGGCTGAGAAC-3′, antisense 5′-TGGTGAAGACGCCAGTGGA-3′; 
β-actin, sense 5′-GGAGATTACTGCCCTGGCTCCTA-3′, antisense 
5′-GACTCATCGTACTCCTGCTTGCTG-3′. Each experiment was performed twice. 
 
Statistical analysis 
All values are expressed as the mean ± SEM.  Differences between groups were 
examined for statistical significance using one-way analysis of variance (ANOVA) 
followed by Scheffe’s test.  A P value less than 0.05 denoted the presence of a 
statistically significant difference. 
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Results 
Metabolic data 
Body weight, kidney weight, urinary albumin excretion, and glycosylated hemoglobin 
are shown in Table 1. Diabetic rats had a significantly lower body weight and higher 
kidney weight per body weight from 4 weeks after the induction of diabetes. An 
increase in urinary albumin excretion was observed after 4 weeks. All diabetic rats 
were moderately hyperglycemic. The serum HbA1c concentration in the diabetic 
group was significantly higher than in the control group. 
 
Phenotype of macrophage in the glomeruli 
Throughout the experiment, ED1, ED2, ED3 and OX-6 positive macrophages are 
analyzed in the glomeruli of control rats and of animals with STZ-induced diabetes (Fig. 
1). When the sections were incubated with irrelevant mouse IgG, no staining was 
observed. The glomeruli of control rats showed only a few ED1, ED2, and ED3 positive 
macrophages. In the rats with STZ-induced diabetes, ED1, which is expressed in pan 
macrophage, peaked at 1 week and maintained to 24 weeks, and most of this 
macrophages are positive for MHC class II (OX-6) in the glomeruli. ED2, which is 
expressed in resident macrophage, was not increased in diabetic glomeruli. 
Sn-positive macrophage (ED3-positive) continued to increase gradually and most of 
these macrophages are also positive for MHC class II in the glomeruli (Fig. 1). 
 
Expression of ICAM-1 
In normal rat glomeruli, ICAM-1 staining was weakly detected. In the glomeruli of 
STZ-induced diabetes, ICAM-1 fluorescence intensity increased early after diabetes 
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induction, reaching a peak at 12 weeks and was significantly higher than in the control 
animals (Fig. 2). A linear ICAM-1 staining pattern was detectable along the capillary 
walls and the mesangial area. 
 
Staining for α-SMA 
In control rats, α-SMA was expressed in the arterioles but not in the glomerular cells. 
The rate of α-SMA-positive glomeruli increased gradually and increased particularly 
from 12 to 24 weeks in diabetic rats (Fig. 3). 
 
Staining for type IV collagen 
In control rats, there was weak staining for type IV collagen throughout the 
experimental period. The expression of type IV collagen increased between 12 weeks 
and 24 weeks in diabetic rats (Fig. 4). 
 
Mesangial matrix area 
Representative glomeruli in PAM stained sections are shown in Fig. 5. Glomerular 
hypertrophy and mesangial matrix expansion were observed in diabetic rat. In 
STZ-induced diabetic rats, mesangial matrix area was increased significantly larger 
than those in control rats (Fig. 5). 
 
Effect of insulin treatment 
A significantly higher body weight and lower kidney weight per body weight were 
observed in the insulin-treated diabetic group than in the untreated diabetic group 
(Table. 1). After 4 weeks of insulin treatment, macrophages infiltrated into diabetic 
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glomeruli decreased to the same level of control rats (Fig. 1), and ICAM-1 expression 
in the diabetic rats was comparable to that in the control rats (Fig.2). The expression of 
α-SMA and type IV collagen, and mesangial matrix area were also suppressed as 
same as the control rats (Fig. 3-5). These results indicated that hyperglycemia but not 
STZ induced the infiltration of macrophages and subsequent histological changes in 
the glomeruli of diabetic rats. 
 
Effects of cytokines and high glucose on the expression of Sn on THP-1 cells  
Sn mRNA expression was significantly increased with concentration dependency by 
the stimulation of IL-1β and TNF-α (Fig. 6). However, Sn expression was not induced 
by hyperglycemic condition or stimulation with IL-4, and TGF-β1. To confirm whether 
IL-1β and TNF-α is upregulated in vivo, we analyzed the gene expression of IL-1β and 
TNF-α in the glomeruli of control and diabetic rats. As shown in Fig. 7, mRNA 
expression of IL-1β and TNF-α is upregulated in diabetic glomeruli. These results 
suggest that Sn might be induced by these inflammatory cytokines in vivo. 
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Discussion 
Sn is expressed on a subpopulation of macrophages with a highly restricted tissue 
distribution in normal conditions including marginal zone macrophages of the spleen, 
sinus macrophages of lymph nodes, and omentum macrophages (23). It is important 
to note that Sn can be rapidly induced in response to serum factors (6), glucocorticoids, 
and cytokines (7). Recent studies in humans have shown that Sn can be expressed 
abundantly on macrophages recruited during pathological conditions including 
multiple sclerosis, atherosclerosis, rheumatoid arthritis, and breast cancer (8). 
Therefore, Sn is suggested to relate to the chronic inflammation and considered as a 
marker of activated macrophages. 
Only a few macrophages are seen in the glomeruli of non diabetic control rats. 
On the other hand, ED1 which is expressed in pan macrophages, peaked at 1 week 
and maintained to 24 weeks, and most of macrophages are positive for MHC class II in 
the glomeruli (Fig. 1C and 1G). ED2 which is expressed in resident macrophages in 
the rats with STZ-induced diabetes (13), did not increase in diabetic glomeruli (Fig. 
1H). Sn-positive macrophages continued to increase gradually and most of these 
macrophages are also positive for MHC class II in the diabetic glomeruli (Fig. 1F and 
1I). Since ICAM-1 expression was significantly upregulated in the diabetic rats 
compared to the control animals (Fig. 2), ICAM-1 may be involved in the infiltration of 
total and Sn-positive macrophages in diabetic glomeruli.  Sn-negative activated 
macrophages are infiltrated in the glomeruli in the early phase of diabetic nephropathy, 
but the proportion of Sn-positive activated macrophages was increased during the 
progression of diabetic nephropathy. These results indicated that Sn-positive 
macrophages may contribute to the chronic inflammation in diabetic nephropathy. 
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We further investigated the correlation of phenotypic change between 
macrophages and mesangial cells in the glomeruli of STZ-induced diabetic rats. The 
α-SMA is considered as a marker for the phenotypic change of mesangial cells (20-21) 
and to play a pivotal role in the accumulation of extracellular matrix in diabetic 
nephropathy. The rate of α-SMA-positive glomeruli increased gradually and increased 
particularly from 12 to 24 weeks in diabetic rats (Fig. 3). Further, the expression of type 
IV collagen increased between 12 weeks and 24 weeks in diabetic rats (Fig. 4), and 
mesangial matrix area in diabetic rats was increased significantly larger than those in 
control rats (Fig. 5). Therefore, the phenotypic change of mesangial cells and 
accumulation of extracellular matrix  was observed in parallel with increase of 
Sn-positive macrophages. 
Sn was originally defined as a sheep erythrocyte receptor on mouse 
macrophages (5-6).  In both mouse and human, the cDNA for Sn encodes a 185-kDa 
type I transmembrane glycoprotein, made up of 17 immunoglobulin-like domains and 
a short cytoplasmic tail (24-25).  Sn is a prototypic member of the Siglec family of sialic 
acid-binding immunoglobulin-like lectins and is also referred to as Siglec-1 (26).  Sn 
was designed CD169 at the seventh human leukocyte differentiation antigen 
workshop. The large extracellular region of Sn contains a sialic acid-binding site within 
the membrane-distal V-set domain and is assumed to extend away from the 
glycocalyx on the cell surface to mediate cell to cell interactions (27). To investigate 
the mechanism of the induction of Sn in macrophages, gene expression of Sn was 
induced by several conditions in THP-1 human monocytic cell line. Sn mRNA 
expression was significantly increased by the stimulation of IL-1β and TNF-α dose 
dependently (Fig. 6). However, Sn expression was not induced by hyperglycemic 
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condition or stimulation with IL-4, and TGF-β1 (Fig. 6). Furthermore, we confirmed that 
mRNA expression of IL-1β and TNF-α is upregulated in diabetic glomeruli (Fig. 7). 
These data indicate that inflammatory cytokines, i.e. IL-1β and TNF-α, but not 
hyperglycemia stimulate the expression of Sn in macrophages. 
Hyperglycemia causes glomerular hyperfiltration and glomerular hypertrophy 
(28-29). Increased intraglomerular pressure caused by hyperfiltration may activate the 
mesangial cells because phenotypic change of mesangial cells is brought about by 
mechanical stress in vitro (30). Growth factors including insulin like growth factor-1 
(IGF-1) and platelet derived growth factor (PDGF) are known to be involved in 
glomerular hypertrophy (31-33) and may play an important role in the phenotypic 
change of mesangial cells. Growth factors such as IGF-1 and PDGF are synthesized 
by macrophages, mesangial cells and others (34-35). From these findings, phenotypic 
change of mesangial cells might be caused by macrophages derived growth factors. 
Although our current study showed that the phenotypic change of mesangial cells was 
in parallel with increase of Sn-positive macrophages, the mechanism of interaction 
between macrophages and mesangial cells remains unclear and further studies are 
needed. 
In conclusion, the current results suggest that macrophages are activated in 
diabetic glomeruli and Sn-positive activated macrophages may contribute to the 
progression of diabetic nephropathy through activation of mesangial cells. 
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Figure Legends 
Figure. 1 Identification of macrophages in diabetic rat glomeruli. Indirect 
immunofluorescent micrographs from diabetic rat glomeruli 24 weeks after STZ 
injection, stained with anti-ED1 (pan-macrophages) (a), anti-ED3 (sialoadhesin 
(Sn)-positive macrophages) (d), anti-OX-6 (MHC class II positive cells) (b, e), anti-ED1 
+ anti-OX-6 (c), anti-ED3 + anti-OX-6 (f). magnification ×200. Intraglomerular 
infiltration by pan-macrophages (ED1) (g), resident macrophages (ED2) (h), and 
Sn-positive macrophages (ED3) (i) in diabetic rats (○), in control rats (●) at 0, 1, 4, 12, 
and 24 weeks, and insulin treated diabetic rats (□) at 4 weeks. A straight line 
represents ED1, ED2, and ED3 and a broken line represents ED1, ED2, and ED3 plus 
OX-6. Data are means±SEM of 50 glomeruli, respectively. *p < 0.05 vs. control, ** p < 
0.01 vs. control, ***p < 0.005 vs. control. 
 
Figure. 2 Identification of ICAM-1 in diabetic glomeruli. Indirect 
immunofluorescent micrographs from control rats at 24 weeks (a) and diabetic rats at 
24 weeks after STZ injection (b), stained with ICAM-1, magnification ×200. c: 
Intraglomerular ICAM-1 expression in control rats (●), diabetic rats (○) at 0, 1, 4, 12, 
and 24 weeks, and insulin treated diabetic rats (□) at 4 weeks. ***p < 0.005 vs. 
control. 
 
Figure. 3 Identification of α-smooth muscle actin (SMA) in diabetic glomeruli. 
Immunoperoxidase staining for α-SMA in control rats at 24 weeks (a) and diabetic rats 
at 24 weeks after STZ injection (b), magnification ×200. c: Intraglomerular α-smooth 
muscle actin expression in control rats (●), diabetic rats (○) at 0, 1, 4, 12, and 24 
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weeks, and insulin treated diabetic rats (□) at 4 weeks. *p < 0.05 vs. control, ** p < 
0.01 vs. control. 
 
Figure. 4 Identification of type IV collagen in diabetic glomeruli. Indirect 
immunofluorescent micrographs from control rats at 24 weeks (a) and diabetic rats at 
24 weeks after STZ injection (b), stained with type IV collagen, magnification ×200. c: 
Intraglomerular type IV collagen expression in control rats (●), diabetic rats (○) at 0, 1, 
4, 12, and 24 weeks, and insulin treated diabetic rats (□) at 4 weeks. *p < 0.05 vs. 
control, ** p < 0.01 vs. control, ***p < 0.005 vs. control. 
 
Figure. 5 Identification and quantification of Periodic acid-methenamine-silver 
(PAM)-positive area in diabetic glomeruli. PAM staining of kidney sections in 
control rats at 24 weeks (a) and diabetic rats at 24 weeks after STZ injection (b), 
magnification ×200. c: Mesangial matrix area is defined as PAM-positive area in the 
tuft area in control rats (●), diabetic rats (○) at 0, 1, 4, 12, and 24 weeks, and insulin 
treated diabetic rats (□) at 4 weeks. *** p < 0.005 vs. control. 
 
Figure. 6 Transcriptional regulation of sialoadhesin (Sn) expression on THP-1 
cells. Sn mRNA expression after 24h exposure to various cytokines or hyperglycemic 
condition was determined by quantitative real-time RT-PCR. HG: hyperglycemic 
condition. HO: hyperosmotic control. n=3 per each group. Data are Mean±SE. *p<0.05 
compared with vehicle (ANOVA). 
 
Figure. 7 Cytokine expressions in rat kidney. mRNA expression of IL-1β and 
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TNF-α was determined by quantitative real-time RT-PCR. mRNA expression of IL-1β 
and TNF-α is upregulated in diabetic glomeruli. n=3 per each group. Data are 
Mean±SE. *p<0.05 compared with vehicle (ANOVA). 
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